Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476)
Year: 2017
Type: article
Source: Annals of Oncology
Institutions: MRC Clinical Trials Unit at UCL, University College London, Cardiff University, Salford Royal NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, University of Glasgow, Kantonsspital St. Gallen, Medical Research Council, Clatterbridge Cancer Centre NHS Foundation Trust, Singleton Hospital, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, Velindre Cancer Centre, Royal Devon & Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital, Exeter Hospital, Royal Devon University Healthcare NHS Foundation Trust, Queen Alexandra Hospital, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2761106140